<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35405150</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-8600</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>131</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Metabolism: clinical and experimental</Title>
          <ISOAbbreviation>Metabolism</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>155200</StartPage>
          <MedlinePgn>155200</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.metabol.2022.155200</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0026-0495(22)00078-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Schisandrin B (Sch B), which inhibits hepatic steatosis caused by non-alcoholic fatty liver disease (NAFLD), is one of the most active dibenzocyclooctadienes isolated from Schisandra chinensis (Turcz.) Baill with various pharmacological activities. In this study, the role of Sch B-induced autophagy in lipid-lowering activities of Sch B was examined and the underlying mechanisms were elucidated.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Free fatty acid (FFA)-stimulated HepG2 cells and mouse primary hepatocytes (MPHs) and high-fat diet (HFD)-fed mice were used as NAFLD models. The role of Sch B-induced autophagy in lipid-lowering effects of Sch B was assessed using ATG5/TFEB-deficient cells and 3-methyladenine (3-MA)-treated hepatocytes and mice.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Sch B simultaneously active autophagy through AMPK/mTOR pathway and decreased the number of lipid droplets in FFA-treated HepG2 cells and MPHs. Additionally, siATG5/siTFEB transfection or 3-MA treatment mitigated Sch B-induced autophagy and activation of fatty acid oxidation (FAO) and ketogenesis in FFA-treated HepG2 cells and MPHs. Sch B markedly decreased hepatic lipid content and activated the autophagy through AMPK/mTOR pathway in HFD-fed mice. However, the activities of Sch B were suppressed upon 3-MA treatment. Sch B upregulated the expression of key enzymes involved in FAO and ketogenesis, which was mitigated upon 3-MA treatment. Moreover, changes in hepatic lipid components and amino acids may be related to the Sch B-induced autophagy pathway.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results suggested that Sch B inhibited hepatic steatosis and promoted FAO by activation of autophagy through AMPK/mTOR pathway. Our study provides novel insights into the hepatic lipophagic activity of Sch B and its potential application in the management of NAFLD.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Li-Shan</ForeName>
            <Initials>LS</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Shuo-Feng</ForeName>
            <Initials>SF</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Gan</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Brian Chi-Yan</ForeName>
            <Initials>BC</Initials>
            <AffiliationInfo>
              <Affiliation>College of Professional and Continuing Education, Hong Kong Polytechnic University, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Chao</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yi-Wei</ForeName>
            <Initials>YW</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiu</LastName>
            <ForeName>Xin-Yu</ForeName>
            <Initials>XY</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Xiao-Hong</ForeName>
            <Initials>XH</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology, Institute of Biochemical Engineering, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qing-Gao</ForeName>
            <Initials>QG</Initials>
            <AffiliationInfo>
              <Affiliation>First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Xue-Lan</ForeName>
            <Initials>XL</Initials>
            <AffiliationInfo>
              <Affiliation>School of Traditional Dai-Thai Medicine, West Yunnan University of Applied Sciences, Jinghong, Yunnan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Si-Yuan</ForeName>
            <Initials>SY</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China; School of Traditional Dai-Thai Medicine, West Yunnan University of Applied Sciences, Jinghong, Yunnan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China. Electronic address: yizhang714@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Metabolism</MedlineTA>
        <NlmUniqueID>0375267</NlmUniqueID>
        <ISSNLinking>0026-0495</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034242">Cyclooctanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005230">Fatty Acids, Nonesterified</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007657">Ketone Bodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017705">Lignans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011083">Polycyclic Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>02XA4X3KZW</RegistryNumber>
          <NameOfSubstance UI="C015499">schizandrin B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.31</RegistryNumber>
          <NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D055372" MajorTopicYN="Y">AMP-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034242" MajorTopicYN="N">Cyclooctanes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059305" MajorTopicYN="N">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005230" MajorTopicYN="N">Fatty Acids, Nonesterified</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022781" MajorTopicYN="N">Hepatocytes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007657" MajorTopicYN="N">Ketone Bodies</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017705" MajorTopicYN="N">Lignans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065626" MajorTopicYN="Y">Non-alcoholic Fatty Liver Disease</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011083" MajorTopicYN="N">Polycyclic Compounds</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">Lipid metabolism</Keyword>
        <Keyword MajorTopicYN="N">Non-alcoholic fatty liver disease</Keyword>
        <Keyword MajorTopicYN="N">Schisandrin B</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>11</Day>
          <Hour>20</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35405150</ArticleId>
        <ArticleId IdType="doi">10.1016/j.metabol.2022.155200</ArticleId>
        <ArticleId IdType="pii">S0026-0495(22)00078-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35405150</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-8600</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>131</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Metabolism: clinical and experimental</Title>
          <ISOAbbreviation>Metabolism</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>155200</StartPage>
          <MedlinePgn>155200</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.metabol.2022.155200</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0026-0495(22)00078-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Schisandrin B (Sch B), which inhibits hepatic steatosis caused by non-alcoholic fatty liver disease (NAFLD), is one of the most active dibenzocyclooctadienes isolated from Schisandra chinensis (Turcz.) Baill with various pharmacological activities. In this study, the role of Sch B-induced autophagy in lipid-lowering activities of Sch B was examined and the underlying mechanisms were elucidated.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Free fatty acid (FFA)-stimulated HepG2 cells and mouse primary hepatocytes (MPHs) and high-fat diet (HFD)-fed mice were used as NAFLD models. The role of Sch B-induced autophagy in lipid-lowering effects of Sch B was assessed using ATG5/TFEB-deficient cells and 3-methyladenine (3-MA)-treated hepatocytes and mice.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Sch B simultaneously active autophagy through AMPK/mTOR pathway and decreased the number of lipid droplets in FFA-treated HepG2 cells and MPHs. Additionally, siATG5/siTFEB transfection or 3-MA treatment mitigated Sch B-induced autophagy and activation of fatty acid oxidation (FAO) and ketogenesis in FFA-treated HepG2 cells and MPHs. Sch B markedly decreased hepatic lipid content and activated the autophagy through AMPK/mTOR pathway in HFD-fed mice. However, the activities of Sch B were suppressed upon 3-MA treatment. Sch B upregulated the expression of key enzymes involved in FAO and ketogenesis, which was mitigated upon 3-MA treatment. Moreover, changes in hepatic lipid components and amino acids may be related to the Sch B-induced autophagy pathway.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results suggested that Sch B inhibited hepatic steatosis and promoted FAO by activation of autophagy through AMPK/mTOR pathway. Our study provides novel insights into the hepatic lipophagic activity of Sch B and its potential application in the management of NAFLD.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Li-Shan</ForeName>
            <Initials>LS</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Shuo-Feng</ForeName>
            <Initials>SF</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Gan</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Brian Chi-Yan</ForeName>
            <Initials>BC</Initials>
            <AffiliationInfo>
              <Affiliation>College of Professional and Continuing Education, Hong Kong Polytechnic University, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Chao</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yi-Wei</ForeName>
            <Initials>YW</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiu</LastName>
            <ForeName>Xin-Yu</ForeName>
            <Initials>XY</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Xiao-Hong</ForeName>
            <Initials>XH</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology, Institute of Biochemical Engineering, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qing-Gao</ForeName>
            <Initials>QG</Initials>
            <AffiliationInfo>
              <Affiliation>First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Xue-Lan</ForeName>
            <Initials>XL</Initials>
            <AffiliationInfo>
              <Affiliation>School of Traditional Dai-Thai Medicine, West Yunnan University of Applied Sciences, Jinghong, Yunnan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Si-Yuan</ForeName>
            <Initials>SY</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China; School of Traditional Dai-Thai Medicine, West Yunnan University of Applied Sciences, Jinghong, Yunnan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China. Electronic address: yizhang714@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Metabolism</MedlineTA>
        <NlmUniqueID>0375267</NlmUniqueID>
        <ISSNLinking>0026-0495</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034242">Cyclooctanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005230">Fatty Acids, Nonesterified</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007657">Ketone Bodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017705">Lignans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011083">Polycyclic Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>02XA4X3KZW</RegistryNumber>
          <NameOfSubstance UI="C015499">schizandrin B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.31</RegistryNumber>
          <NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D055372" MajorTopicYN="Y">AMP-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034242" MajorTopicYN="N">Cyclooctanes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059305" MajorTopicYN="N">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005230" MajorTopicYN="N">Fatty Acids, Nonesterified</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022781" MajorTopicYN="N">Hepatocytes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007657" MajorTopicYN="N">Ketone Bodies</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017705" MajorTopicYN="N">Lignans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065626" MajorTopicYN="Y">Non-alcoholic Fatty Liver Disease</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011083" MajorTopicYN="N">Polycyclic Compounds</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">Lipid metabolism</Keyword>
        <Keyword MajorTopicYN="N">Non-alcoholic fatty liver disease</Keyword>
        <Keyword MajorTopicYN="N">Schisandrin B</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>11</Day>
          <Hour>20</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35405150</ArticleId>
        <ArticleId IdType="doi">10.1016/j.metabol.2022.155200</ArticleId>
        <ArticleId IdType="pii">S0026-0495(22)00078-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
